ATR and cancer: To summarize, these results suggest that the Atr-Chek1 pathway also functions intrinsically in neurons to inhibit axon regeneration in mammals, a process that may be evolutionarily conserved, and that the anti-cancer drugs targeting Atr-Chek1 may be repurposed for treating neural injury.